Leaps by Bayer, the impact investment arm of Bayer, led a $105m Series B round in Senti Bio, a biotechnology company, with participation from Matrix Partners China, Mirae Asset Capital, Ridgeback Capital, Intel Capital, New Enterprise Associates, 8VC, Amgen Ventures and Lux Capital. "Leaps by Bayer’s mission is to invest in breakthrough technologies that may transform the lives of millions of patients for the better. We believe that synthetic biology will become an important pillar in next-generation cell and gene therapy, and that Senti Bio’s leadership in designing and optimizing biological circuits fits precisely with our ambition to prevent and cure cancer and to regenerate lost tissue function," Juergen Eckhardt, Leaps by Bayer Head.